NGS-Based RNA-Sequencing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The NGS-Based RNA-Sequencing Market is segmented by Product & Services (Sequencing Platform & Consumables and Sequencing Services), Technology (Nanopore Sequencing, Sequencing by Synthesis, Ion Semiconductor Sequencing and Single-Molecule Real-Time Sequencing), Application (Drug Discovery, Diagnostics, Precision Medicine and Others), End User (Biotechnology & Pharmaceutical Companies, Research Centers, Academic & Government Institutes, Hospitals & Clinics, and Others) Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

USD
Study Period: 2018-2026
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 19.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The NGS-Based RNA-Sequencing Market studied is expected to grow with an estimated CAGR of 19.6%, over the forecast period.

Next-generation sequencing has turn out to be the investigational tool for several researchers in the fight against the COVID-19 pandemic. RNA-sequencing precisely is crucial in serving to update the understanding of infection dynamics and viral pathogenesis of the SARS-CoV-2 virus. Numerous advanced studies were undertaken in order to understand the ever-changing aspects and epidemiology of the virus across various countries using single-cell RNA sequencing, stranded RNA-sequencing, and ultra-low input RNA-sequencing. A comprehensive investigation of the SARS-CoV-2 virus was carried out in order to reveal the molecular mechanisms and hub genes based on a genome-wide RNA sequencing dataset. This has greatly boosted the research and development activities in clinical studies with NGS as their basis of innovation. Thus, in the context of the ongoing pandemic, the NGS-based RNA-Sequencing market is projected to be positively impacted by COVID-19.

Factors such as surge in the number of product approvals for RNA-sequencing platforms and consumables, advancements in data analysis & storage, automation in sample generation techniques, as well as augmenting genomic research in the fields of rare genetic diseases and autoimmune diseases are leading to growth in adoption of NGS-based RNA-Sequencing products. Additionally, customization of healthcare procedures as per the needs of patient’s medical records, treatments, and practices (precision medicine) is also anticipated to enhance the entire drug delivery process rather than considering the one-size-fits-all approach. This has resulted in an increase in genomic research activities and precision medicine has evolved as a vital focus of biomedical research. These practices are all set to increase the acceptance of NGS-based RNA-sequencing in near future.

Furthermore, NGS-based RNA-sequencing offers several advantages over the conventional methods for transcriptome analysis with cost-effective procedures. Since it allows direct quantification and identification of transcripts, it is becoming a de facto standard approach for investigating and optimizing mammalian cells. In addition, NGS-based RNA-sequencing eliminates non-ideal hybridization and cross-hybridization as observed in microarrays. This technique provides absolute values with higher specificityand can quantify large dynamic range of expression levels. Since NGS-based RNA-sequencing allows the detection of novel transcripts, this technology is emerging as an alternative to whole-genome transcriptome profiling. Therefore, these aforementioned factors are collectively responsible for the growth of the NGS-based RNA-sequencing market over the analysis period. Conversely, interpretation of complex data and lack of skilled professionals and lack of standardization are expected to hinder the market growth in the coming years.

Scope of the Report

As per the scope of the report, NGS-Based RNA-Sequencing is a technology used in identifying and determining the order of nucleotides in an RNA sequence. This technique plays a vital role in analyzing transcriptomics and gene expression. NGS-Based RNA-Sequencing is a faster and more reliable technology to obtain genetic information from samples, and at a lower cost than ever before with a significant increase in throughput capabilities.

The NGS-Based RNA-Sequencing Market is segmented by Product & Services (Sequencing Platform & Consumables and Sequencing Services), Technology (Nanopore Sequencing, Sequencing by Synthesis, Ion Semiconductor Sequencing, and Single-Molecule Real-Time Sequencing), Application (Drug Discovery, Diagnostics, Precision Medicine and Others), End User (Biotechnology & Pharmaceutical Companies, Research Centers, Academic & Government Institutes, Hospitals & Clinics, and Others) Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Product and Services
Sequencing Platform and Consumables
Sequencing Services
By Technology
Nanopore Sequencing
Sequencing by Synthesis
Ion Semiconductor Sequencing
Single Molecule Real Time Sequencing
By Application
Drug Discovery
Diagnostics
Precision Medicine
Others
By End User
Biotechnology and Pharmaceutical Companies
Research Centers, Academic and Government Institutes
Hospitals and Clinics
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

RNA Sequencing Platform & Consumables Segment is Expected to Hold the Largest Market Share in the NGS-Based RNA-Sequencing Market

Based on product & services, the RNA sequencing platform & consumables segment is projected to hold the largest market share throughout the forecast period. This growth is majorly attributed to the availability of innovative RNA sequencing platforms provided by key market players. Some of these platforms include Illumina HiSeq, SOLiD systems, Oxford Nanopore Technologies (ONT) Nanopore sequencing, Ion Torrent, and PacBio IsoSeq, among others. These platforms have revolutionized the study of transcriptome by providing researchers the perceptibility to acknowledge the changes in the diseased state of an individual that previously went undetected. RNA sequencing platform & consumables allow measuring transcriptome expression by detecting gene fusions, transcript isoforms, and single nucleotide variants. Moreover, technological advancements in the field of next-generation sequencing techniques and continuous R&D efforts of biotechnological companies for manufacturing cost-effective and innovative RNA sequencing platforms for cancer research are also boosting the market growth over the forecast period. Technological advancements such as RNA interference (RNAi) improve accuracy and precision, thereby, assisting researchers in analyzing the transcriptional activity. For instance, NGS tools manufactured by Illumina, Inc., are highly successful in fragmenting RNA into several pieces, sequencing the libraries, adding adapters, and reassembling them to form a genomic sequence.

Cancer

North America is Expected to Hold a Major Share of the Market throughout the Forecast Period

Within North America, the United States has held the major share of the market and is expected to dominate over the forecast period. The presence of major biotechnological research companies such as Illumina, Inc., Thermo Fischer Scientific Inc., Agilent Technologies, Inc., PerkinElmer Inc., and GENEWIZ, Inc. in the region coupled with the early adoption of NGS technology contribute toward the growth of the market. Upsurge in funding from the private players and federal government, as well as the increased implementation of RNA sequencing technologies by non-government and government bodies for biomedical and genomic research purposes, is anticipated to enhance the adoption of NGS-based RNA-sequencing techniques, majorly in the United States. Likewise, the increasing prevalence of systemic autoimmune and oncologic diseases together with progressions in gene expression and regulation studies are likely to drive the growth of the NGS-Based RNA-Sequencing Market in North America. For instance, systemic autoimmune disease such as rheumatoid arthritis is one of the most common autoimmune disorders and has affected over 1.3 million Americans in 2018, as per Rheumatoid Arthritis Organization.

Geography

Competitive Landscape

The NGS-Based RNA-Sequencing market is moderately competitive with several players across the globe. In terms of market share, various major players currently dominate the market. With the increase in research and development activity, many regional players are expected to be part of the NGS-Based RNA-Sequencing Market over the forecast period. Some of the major players of the market are Illumina, Inc., Oxford Nanopore Technologies, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., PerkinElmer, Inc., F. Hoffmann-La Roche Ltd, Hamilton Company, and Takara Bio Inc. among others.

Recent Developments

  • In May 2021, Bio-Rad Laboratories, Inc. launched SEQuoia RiboDepletion Kit for NGS that eliminates irrelevant ribosomal RNA from the RNA-sequencing library and improves assay efficiency.
  • In December 2020, Tecan Trading AG launched Revelo RNA-Seq kit that processes human samples and analyzes complete viral RNA-sequencing library preparation within a single day.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Surge in products approvals for RNA-sequencing platforms and consumables

      2. 4.2.2 Advancements in precision medicine

      3. 4.2.3 Advantages of NGS-based RNA-sequencing

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of standardization

      2. 4.3.2 Interpretation Of Complex Data And Lack Of Skilled Professionals

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product and Services

      1. 5.1.1 Sequencing Platform and Consumables

      2. 5.1.2 Sequencing Services

    2. 5.2 By Technology

      1. 5.2.1 Nanopore Sequencing

      2. 5.2.2 Sequencing by Synthesis

      3. 5.2.3 Ion Semiconductor Sequencing

      4. 5.2.4 Single Molecule Real Time Sequencing

    3. 5.3 By Application

      1. 5.3.1 Drug Discovery

      2. 5.3.2 Diagnostics

      3. 5.3.3 Precision Medicine

      4. 5.3.4 Others

    4. 5.4 By End User

      1. 5.4.1 Biotechnology and Pharmaceutical Companies

      2. 5.4.2 Research Centers, Academic and Government Institutes

      3. 5.4.3 Hospitals and Clinics

      4. 5.4.4 Others

    5. 5.5 Geography

      1. 5.5.1 North America

        1. 5.5.1.1 United States

        2. 5.5.1.2 Canada

        3. 5.5.1.3 Mexico

      2. 5.5.2 Europe

        1. 5.5.2.1 Germany

        2. 5.5.2.2 United Kingdom

        3. 5.5.2.3 France

        4. 5.5.2.4 Italy

        5. 5.5.2.5 Spain

        6. 5.5.2.6 Rest of Europe

      3. 5.5.3 Asia-Pacific

        1. 5.5.3.1 China

        2. 5.5.3.2 Japan

        3. 5.5.3.3 India

        4. 5.5.3.4 Australia

        5. 5.5.3.5 South Korea

        6. 5.5.3.6 Rest of Asia-Pacific

      4. 5.5.4 Middle East and Africa

        1. 5.5.4.1 GCC

        2. 5.5.4.2 South Africa

        3. 5.5.4.3 Rest of Middle East and Africa

      5. 5.5.5 South America

        1. 5.5.5.1 Brazil

        2. 5.5.5.2 Argentina

        3. 5.5.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Agilent Technologies, Inc.

      2. 6.1.2 Bio-Rad Laboratories, Inc.

      3. 6.1.3 F. Hoffmann-La Roche Ltd.

      4. 6.1.4 Hamilton Company

      5. 6.1.5 Illumina,Inc.

      6. 6.1.6 Oxford Nanopore Technologies

      7. 6.1.7 PerkinElmer, Inc.

      8. 6.1.8 Takara Bio Inc.

      9. 6.1.9 Tecan Trading AG

      10. 6.1.10 Thermo Fisher Scientific Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products, Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The NGS-Based RNA-Sequencing Market market is studied from 2018 - 2026.

The NGS-Based RNA-Sequencing Market is growing at a CAGR of 19.6% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Illumina, Inc., Oxford Nanopore Technologies, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., PerkinElmer, Inc. are the major companies operating in NGS-Based RNA-Sequencing Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!